COVID-19 and Lipid Disorders

Abstract

An elevated cholesterol concentration has been suspected to increase the susceptibility for SARS-COV-2 infection. Cholesterol plays a central role in the mechanisms of the SARS-COV-2 infection. In contrast, higher HDL-cholesterol levels seem to be protective. During COVID-19 disease, LDL-cholesterol and HDL-cholesterol appear to be decreased. On the other hand, triglycerides (also in different lipoprotein fractions) were elevated. Lipoprotein(a) may increase during this disease and is most probably responsible for thromboembolic events. This lipoprotein can induce a progression of atherosclerotic lesion formation. The same is suspected for the SARS-COV-2 infection itself. COVID-19 patients are at increased risk of incident cardiovascular diseases, including cerebrovascular disorders, dysrhythmias, ischemic and non-ischemic heart disease, pericarditis, myocarditis, heart failure, and thromboembolic disorders. An ongoing lipid-lowering therapy, including lipoprotein apheresis, is recommended to be continued during the COVID-19 disease, though the impact of lipid-lowering drugs or the extracorporeal therapy on prognosis should be studied in further investigations.

Key words

cardiovascular diseases - COVID-19 - high-density lipoprotein - lipid-lowering therapy - lipoprotein(a) - low-density lipoprotein

Publication History

Received: 17 March 2022

Accepted after revision: 12 May 2022

Article published online:
14 July 2022

• References

• 1 Katsoularis I, Fonseca-Rodriguez O, Farrington P. et al. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet 2021; 398: 599-607
• 2 Xie Y, Xu E, Bowe B. et al. Long-term cardiovascular outcomes of COVID-19. Nat Med 2022; 28: 583-590
• 3 Cure E, Cumhur Cure M. Strong relationship between cholesterol, low-density lipoprotein receptor, Na(+)/H(+) exchanger, and SARS-COV-2: this association may be the cause of death in the patient with COVID-19. Lipids Health Dis 2021; 20: 179
• 4 Hofmann A, Brunssen C, Wolk S. et al. Soluble LOX-1: a novel biomarker in patients with coronary artery disease, stroke, and acute aortic dissection?. J Am Heart Assoc 2020; 9: e013803
• 5 Punch E, Klein J, Diaba-Nuhoho P. et al. Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis. J Am Heart Assoc 2022; 11: e023328
• 6 Feingold KR. Lipid and lipoprotein levels in patients with COVID-19 infections. In: Feingold KR, Anawalt B, Boyce A et al. (eds), Endotext. South Dartmouth (MA). 2020
• 7 Morawietz H, Julius U, Bornstein SR. Cardiovascular diseases, lipid-lowering therapies and European registries in the COVID-19 pandemic. Cardiovasc Res 2020; 116: e122-e125
• 8 Bornstein SR, Voit-Bak K, Schmidt D. et al. Is there a role for environmental and metabolic factors predisposing to severe COVID-19?. Horm Metab Res 2020; 52: 540-546
• 9 Demiray A, Kanbay A, Kanbay M. Long-term effect of COVID-19 infection on hemodialysis patients: should we follow hemodialysis patients more closely?. Clin Kidney J 2022; 15: 369-371
• 10 Stumpf J, Siepmann T, Lindner T. et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur 2021; 9: 100178
• 11 Sarmadi M, Ahmadi-Soleimani SM, Fararouei M. et al. COVID-19, body mass index and cholesterol: an ecological study using global data. BMC Public Health 2021; 21: 1712
• 12 Vuorio A, Kovanen PT, Santos RD. et al. Prevention of cardiovascular burden in COVID-19 patients suffering from familial hypercholesterolemia: a global challenge. Cardiol Ther 2021; 11: 1-7
• 13 Myers KD, Wilemon K, McGowan MP. et al. COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD. Am J Prev Cardiol 2021; 7: 100197
• 14 Scalsky RJ, Chen YJ, Desai K. et al. Baseline cardiometabolic profiles and SARS-CoV-2 infection in the UK biobank. PLoS One 2021; 16: e0248602
• 15 Sun Y, Chatterjee R, Ronanki A. et al. Circulating polyunsaturated fatty acids and COVID-19: a prospective cohort study and Mendelian randomization analysis. medRxiv 2022;
• 16 Salabei JK, Asnake ZT, Ismail ZH. et al. COVID-19 and the cardiovascular system: an update. Am J Med Sci 2022; S0002-9629(22)00069-6
• 17 Henein MY, Cameli M, Pastore MC. et al. COVID-19 severity and cardiovascular disease: an inseparable link. J Clin Med 2022; 11: 479
• 18 Youn JY, Zhang Y, Wu Y. et al. Therapeutic application of estrogen for COVID-19: attenuation of SARS-CoV-2 spike protein and IL-6 stimulated, ACE2-dependent NOX2 activation, ROS production and MCP-1 upregulation in endothelial cells. Redox Biol 2021; 46: 102099
• 19 Catar R, Chen L, Zhao H. et al. Native and oxidized low-density lipoproteins increase the expression of the LDL receptor and the LOX-1 receptor, respectively, in arterial endothelial cells. Cells 2022; 11: 204
• 20 Catar RA, Muller G, Heidler J. et al. Low-density lipoproteins induce the renin-angiotensin system and their receptors in human endothelial cells. Horm Metab Res 2007; 39: 801-805
• 21 Montiel V, Lobysheva I, Gerard L. et al. Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. EBioMedicine 2022; 77: 103893
• 22 Hofmann A, Brunssen C, Morawietz H. Contribution of lectin-like oxidized low-density lipoprotein receptor-1 and LOX-1 modulating compounds to vascular diseases. Vascul Pharmacol 2018; 107: 1-11
• 23 Hu X, Chen D, Wu L. et al. Declined serum high density lipoprotein cholesterol is associated with the severity of COVID-19 infection. Clin Chim Acta 2020; 510: 105-110
• 24 Zinellu A, Paliogiannis P, Fois AG. et al. Cholesterol and triglyceride concentrations, COVID-19 severity, and mortality: a systematic review and meta-analysis with meta-regression. Front Public Health 2021; 9: 705916
• 25 Zhao M, Luo Z, He H. et al. Decreased low-density lipoprotein cholesterol level indicates poor prognosis of severe and critical COVID-19 patients: a retrospective, single-center study. Front Med (Lausanne) 2021; 8: 585851
• 26 Wang G, Deng J, Li J. et al. The role of high-density lipoprotein in COVID-19. Front Pharmacol 2021; 12: 720283
• 27 Wang Y, Zhang J, Li H. et al. Prognostic value of leucocyte to high-density lipoprotein-cholesterol ratios in COVID-19 patients and the diabetes subgroup. Front Endocrinol (Lausanne) 2021; 12: 727419
• 28 Aparisi A, Iglesias-Echeverria C, Ybarra-Falcon C. et al. Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19. Nutr Metab Cardiovasc Dis 2021; 31: 2619-2627
• 29 Masana L, Correig E, Ibarretxe D. et al. Low HDL and high triglycerides predict COVID-19 severity. Sci Rep 2021; 11: 7217
• 30 Bruzzone C, Bizkarguenaga M, Gil-Redondo R. et al. SARS-CoV-2 infection dysregulates the metabolomic and lipidomic profiles of serum. iScience 2020; 23: 101645
• 31 Schmelter F, Foh B, Mallagaray A. et al. Metabolic and lipidomic markers differentiate COVID-19 from non-hospitalized and other intensive care patients. Front Mol Biosci 2021; 8: 737039
• 32 Valdes A, Moreno LO, Rello SR. et al. Metabolomics study of COVID-19 patients in four different clinical stages. Sci Rep 2022; 12: 1650
• 33 Lippi G, Szergyuk I, de Oliveira MHS. et al. The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury. J Thromb Thrombolysis 2022; 53: 581-585
• 34 Vuorio A, Kaste M, Kovanen PT. Elevated lipoprotein(a) and cerebral venous sinus thrombosis in COVID-19. J Stroke Cerebrovasc Dis 2021; 30: 105865
• 35 Nurmohamed NS, Collard D, Reeskamp LF. et al. Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study. Atherosclerosis 2021; 341: 43-49
• 36 Moriarty PM, Gorby LK, Stroes ES. et al. Lipoprotein(a) and its potential association with thrombosis and inflammation in COVID-19: a testable hypothesis. Curr Atheroscler Rep 2020; 22: 48
• 37 Evans PC, Rainger GE, Mason JC. et al. Endothelial dysfunction in COVID-19: a position paper of the ESC working group for atherosclerosis and vascular biology, and the ESC council of basic cardiovascular science. Cardiovasc Res 2020; 116: 2177-2184
• 38 Task Force for the management of COVID-19 of the European Society of Cardiology. European society of cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis. Cardiovasc Res 2021;
• 39 Iqbal Z, Ho JH, Adam S. et al. Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. Atherosclerosis 2020; 313: 126-136
• 40 Muller G, Morawietz H. NAD(P)H oxidase and endothelial dysfunction. Horm Metab Res 2009; 41: 152-158
• 41 Kovanen PT, Raal F, Vuorio A. Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction. Am J Prev Cardiol 2021; 7: 100224
• 42 Audrey J, Wisnu W, Tahapary DL. Association between statin use and poor outcomes in COVID-19 patients with diabetes mellitus: a systematic review. Curr Diabetes Rev 2022; Online ahead of print
• 43 Vinciguerra M, Romiti S, Sangiorgi GM. et al. SARS-CoV-2 and atherosclerosis: should COVID-19 be recognized as a new predisposing cardiovascular risk factor?. J Cardiovasc Dev Dis 2021; 8: 130
• 44 Tan WYT, Young BE, Lye DC. et al. Statin use is associated with lower disease severity in COVID-19 infection. Sci Rep 2020; 10: 17458
• 45 Byttebier G, Belmans L, Alexander M. et al. Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs. Hum Vaccin Immunother 2021; 17: 2841-2850
• 46 Almeida SO, Budoff M. Effect of statins on atherosclerotic plaque. Trends Cardiovasc Med 2019; 29: 451-455
• 47 Vuorio A, Raal F, Klingel R. et al. Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19. J Clin Lipidol 2021; 15: 379-380